Meeting News CoverageVideo

VIDEO: Sun Ophthalmics poised to launch BromSite, Xelpros

CHICAGO — At the Ophthalmology Innovation Summit here Jerry St. Peter, vice president and head of Sun Ophthalmics, discusses the intended November launch of BromSite (bromfenac ophthalmic solution 0.075%), a nonsteroidal anti-inflammatory drug that has been FDA-approved for prevention of ocular pain and treatment of postoperative inflammation in patients undergoing cataract surgery. As well, St. Peter anticipates the future launch of Xelpros (0.005% latanoprost) for the treatment of glaucoma.

CHICAGO — At the Ophthalmology Innovation Summit here Jerry St. Peter, vice president and head of Sun Ophthalmics, discusses the intended November launch of BromSite (bromfenac ophthalmic solution 0.075%), a nonsteroidal anti-inflammatory drug that has been FDA-approved for prevention of ocular pain and treatment of postoperative inflammation in patients undergoing cataract surgery. As well, St. Peter anticipates the future launch of Xelpros (0.005% latanoprost) for the treatment of glaucoma.

    See more from American Academy of Ophthalmology Meeting